CN101838273B - Method for Extracting Strychnine from Nuxychnium - Google Patents
Method for Extracting Strychnine from Nuxychnium Download PDFInfo
- Publication number
- CN101838273B CN101838273B CN2010101743732A CN201010174373A CN101838273B CN 101838273 B CN101838273 B CN 101838273B CN 2010101743732 A CN2010101743732 A CN 2010101743732A CN 201010174373 A CN201010174373 A CN 201010174373A CN 101838273 B CN101838273 B CN 101838273B
- Authority
- CN
- China
- Prior art keywords
- strychnine
- precipitate
- chitosan
- yunnan
- adjust
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 title claims abstract description 49
- 229960005453 strychnine Drugs 0.000 title claims abstract description 30
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 18
- 241001279009 Strychnos toxifera Species 0.000 title abstract description 20
- 239000002244 precipitate Substances 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 238000005352 clarification Methods 0.000 claims abstract description 7
- 238000001179 sorption measurement Methods 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims abstract description 3
- 238000001953 recrystallisation Methods 0.000 claims abstract description 3
- 238000002425 crystallisation Methods 0.000 claims abstract 3
- 230000008025 crystallization Effects 0.000 claims abstract 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- 229920001661 Chitosan Polymers 0.000 claims description 13
- 239000012141 concentrate Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 235000012054 meals Nutrition 0.000 claims description 6
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 238000005189 flocculation Methods 0.000 claims description 2
- 230000016615 flocculation Effects 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 239000000706 filtrate Substances 0.000 abstract description 7
- 239000003513 alkali Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000003912 environmental pollution Methods 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- HCCFPODVEOBUMM-YOQTYQRRSA-N pseudostrychnine Chemical compound O([C@H]1CC2=O)CC=C3CN4CC[C@@]56C7=CC=CC=C7N2[C@H]6[C@H]1[C@H]3C[C@@]54O HCCFPODVEOBUMM-YOQTYQRRSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 239000008395 clarifying agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- ADTDBAKUQAKBGZ-VXJIXCKJSA-N strychnine N-oxide Chemical compound O([C@H]1CC(=O)N(C=2C3=CC=CC=2)[C@H]2[C@H]1[C@H]1C4)CC=C1C[N+]1([O-])[C@@H]4[C@]23CC1 ADTDBAKUQAKBGZ-VXJIXCKJSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- PCGVPMHGSJFFTI-ZEYGOCRCSA-N (4ar,5as,8ar,13as,15as,15br)-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2h-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline-14-one;nitric acid Chemical compound O[N+]([O-])=O.O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 PCGVPMHGSJFFTI-ZEYGOCRCSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical group O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- -1 polyethylene terephthalate phenol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- REFMEZARFCPESH-UHFFFAOYSA-M sodium;heptane-1-sulfonate Chemical compound [Na+].CCCCCCCS([O-])(=O)=O REFMEZARFCPESH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940059935 strychnine nitrate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了从中药马钱子中提取士的宁的方法,包括以下步骤:(1)马钱子粗粉,水回流提取,浓缩提取液;(2)浓缩液加入高分子絮凝剂进行吸附澄清;(3)澄清液加碱调节碱性,收集沉淀A;(4)稀硫酸溶解沉淀A,滤去不溶物,滤液调碱性析出沉淀B;(5)稀盐酸溶解沉淀B,结晶,得盐酸士的宁粗结晶;(6)盐酸士的宁重结晶。本方法与传统的士的宁制备技术相比,具有环境污染小、生产成本低、产品纯度高的优势。The invention discloses a method for extracting strychnine from the traditional Chinese medicine Nuxychnium, which comprises the following steps: (1) Nuxychnium coarse powder is extracted with water reflux, and the extract is concentrated; (2) The concentrated solution is added with a polymer flocculant for adsorption Clarification; (3) add alkali to the clarified liquid to adjust the alkalinity, and collect the precipitate A; (4) dissolve the precipitate A with dilute sulfuric acid, filter off the insoluble matter, adjust the filtrate to alkalinity and precipitate the precipitate B; (5) dissolve the precipitate B with dilute hydrochloric acid, crystallize, Obtain coarse crystallization of strychnine hydrochloride; (6) recrystallization of strychnine hydrochloride. Compared with the traditional strychnine preparation technology, the method has the advantages of little environmental pollution, low production cost and high product purity.
Description
技术领域 technical field
本发明涉及一种从马钱子中提取士的宁的方法。The invention relates to a method for extracting strychnine from Nuxychnium.
背景技术 Background technique
马钱子性味苦、寒,有大毒,归肝、脾经,有散结消肿、通络止痛之功效,用于跌打损伤、肿痛、风湿麻痹、类风湿关节痛、麻木瘫痪等病症。马钱子主要活性成分为吲哚类生物碱,总生物碱含量约为3%-5%,其中士的宁(strychnine)和马钱子碱(brucine)约占80%,尚含番木鳖次碱、马钱子新碱、伪番木鳖碱、伪马钱子碱、番木鳖碱N氧化物、马钱子碱N氧化物等多种生物碱。士的宁能竞争性与脊髓甘氨酸受体结合,阻断甘氨酸对脊髓有抑制作用,可提高骨骼肌的紧张度;小剂量应用士的宁可兴奋大脑皮层的感觉分析器,使视觉、听觉及嗅觉更为敏锐。硝酸士的宁注射液为药典二部收录品种,规格为1ml∶1mg、1ml∶2mg,临床上用于巴比妥类药物中毒、偏瘫、弱视的治疗。Nuxychia is bitter in nature and flavor, cold, has great poison, returns to liver, spleen meridian, has the effect of dispelling stagnation, reducing swelling, dredging collaterals and relieving pain, and is used for bruises, swelling and pain, rheumatic paralysis, rheumatoid arthralgia, numbness and paralysis and other diseases. Nuxychnium main active ingredients are indole alkaloids, the total alkaloid content is about 3%-5%, of which strychnine (strychnine) and strychnine (brucine) account for about 80%. Hypoxine, strychnine, pseudo strychnine, pseudo strychnine, strychnine N oxide, strychnine N oxide and other alkaloids. Strychnine can competitively bind to glycine receptors in the spinal cord, blocking glycine has an inhibitory effect on the spinal cord, and can increase the tension of skeletal muscles; small doses of strychnine can excite the sensory analyzer of the cerebral cortex, making vision, hearing and smell Sharper. Strychnine nitrate injection is a species included in the second part of the Pharmacopoeia, with specifications of 1ml: 1mg and 1ml: 2mg. It is clinically used for the treatment of barbiturate poisoning, hemiplegia, and amblyopia.
马钱子水提液十分混浊,是一种复杂的固液分散体系,由真溶液、胶体溶液、乳浊液和混悬液组成的混合分散体系。马钱子水提取液的微粒按组成分为药渣性微粒(药材组织物)、难溶性和不溶性成分的多分子聚集体、细胞碎片及其聚集物。微粒一般具有亲水性、带有电荷和双电层、微粒之间存在范德华力作用、双电层相互排斥作用、溶剂化作用、疏水化作用、空间位阻效应等相互作用;马钱子为种子类药材,含大量淀粉、蛋白质等水溶大分子物质,水溶性大分子是天然的表面活性剂,具有增溶、助悬、乳化、润湿的作用,且可作为疏水性胶体的保护物,从而使难溶性成分、乳浊液微滴、固体微粒在水中具有较强的稳定性。马钱子表面长满细密的茸毛,其水提液含有大量茸毛,即使采用乙醇沉淀的方法也难以除尽。将马钱子水提液浓缩后,调节PH值至碱性,用亲脂性有机溶剂萃取过程中极易乳化,萃取操作难以完成。有机絮凝剂是一种高分子聚合物,它的分子量很大,通过长碳链上的一些活性官能团可以吸附马钱子水提液的微粒。由于絮凝剂是较长的线状结构,有许多官能团,在同一个分子上可吸附多个微粒,因而它在微粒之间起了联系的作用,这种作用称为架桥作用。因此絮凝剂可以将许多微粒连结在一起形成一个絮团,絮团逐渐增长变成较大的絮团,因而加快了微粒的沉降速度。马钱子水提液吸附澄清后,可以混浊状态变为澄清的液体,提取液中杂质大大减少。The water extract of Nyx nuxica is very turbid, and it is a complex solid-liquid dispersion system, which is a mixed dispersion system composed of true solution, colloidal solution, emulsion and suspension. The microparticles of the water extract of Nyxa nuxicae can be divided into medicinal dregs microparticles (medicinal material tissue), multi-molecular aggregates of insoluble and insoluble components, cell fragments and aggregates according to the composition. Particles generally have hydrophilicity, charge and electric double layer, and there are interactions such as Van der Waals force, electric double layer mutual repulsion, solvation, hydrophobization, steric hindrance effect and other interactions between particles; Seed medicinal materials contain a large amount of water-soluble macromolecules such as starch and protein. Water-soluble macromolecules are natural surfactants, which have the functions of solubilizing, suspending, emulsifying, and wetting, and can be used as protective materials for hydrophobic colloids. Therefore, insoluble components, emulsion droplets, and solid particles have strong stability in water. The surface of Nuxynum is covered with fine and dense hairs, and its water extract contains a large amount of hairs, which are difficult to remove even by ethanol precipitation. After concentrating the water extract of Nyxa nuxica, adjust the pH value to alkaline, and it is very easy to emulsify during the extraction process with a lipophilic organic solvent, and the extraction operation is difficult to complete. The organic flocculant is a kind of high molecular weight polymer, its molecular weight is very large, and some active functional groups on the long carbon chain can absorb the particles of the water extract of Nuxebra chinensis. Since the flocculant is a long linear structure with many functional groups, it can adsorb multiple particles on the same molecule, so it acts as a link between the particles. This effect is called bridging. Therefore, the flocculant can link many particles together to form a floc, which gradually grows into a larger floc, thus accelerating the settling speed of the particles. After adsorption and clarification, the water extract of Nuxebra chinensis can change from a turbid state to a clear liquid, and the impurities in the extract are greatly reduced.
发明内容 Contents of the invention
本发明目的在于提供一种环境友好、低成本从马钱子提取士的宁的方法。The purpose of the present invention is to provide an environment-friendly and low-cost method for extracting strychnine from Nuxychnium.
本发明目的通过以下技术方案实现的,包括以下步骤:The object of the present invention is achieved through the following technical solutions, comprising the following steps:
(1)马钱子粗粉(全部通过10目筛,通过50目筛粉末不超过20%),水回流提取,浓缩提取液;(1) Nuxychnium coarse powder (all passing through a 10-mesh sieve, no more than 20% of the powder passing through a 50-mesh sieve), water reflux extraction, and concentrated extract;
(2)浓缩液加高分子絮凝剂吸附澄清;(2) The concentrated solution is added with a polymer flocculant for adsorption and clarification;
(3)澄清液加碱调节碱性,收集沉淀A;(3) add alkali to the clarified liquid to adjust the alkalinity, and collect the precipitate A;
(4)稀酸溶解沉淀A,滤去不溶物,滤液调碱性析出沉淀B;(4) Precipitate A is dissolved with dilute acid, the insoluble matter is filtered off, and the filtrate is adjusted to be alkaline to precipitate Precipitate B;
(5)稀盐酸溶解沉淀B,结晶,得盐酸士的宁粗结晶;(5) Dilute hydrochloric acid dissolves the precipitate B, crystallizes, and obtains strychnine hydrochloride coarse crystals;
(6)重结晶。(6) Recrystallization.
步骤(1)水用量为马钱子质量5-16倍,加热到回流提取1-4次,时间60-180分钟;浓缩可为常温或减压浓缩,优选为减压浓缩;浓缩比例为马钱子粗粉∶浓缩液=1g∶2-10ml。Step (1) The amount of water used is 5-16 times the mass of Nuxyche, heated to reflux and extracted 1-4 times, and the time is 60-180 minutes; the concentration can be at room temperature or under reduced pressure, preferably under reduced pressure; the concentration ratio is Qianzi coarse powder: concentrated solution = 1g: 2-10ml.
步骤(2)絮凝剂可为明胶、海藻酸钠、琼脂、甲壳素及其衍生物、壳聚糖、101果汁澄清剂、聚凝净、ZTC1十1天然澄清剂、交联聚维酮、聚丙烯酸钠、聚对苯二甲酸乙二醇酪中的一种,优选絮凝剂为壳聚糖;具体的是在100ml浓缩液加入1%壳聚糖的乙酸溶液(1g壳聚糖溶解于100ml1%的乙酸溶液中)10-50ml,优选20-35ml;絮凝温度为20-90℃,较好温度为60-80℃,澄清时间为30-300分钟。Step (2) The flocculant can be gelatin, sodium alginate, agar, chitin and its derivatives, chitosan, 101 fruit juice clarifying agent, polycondensate, ZTC1+1 natural clarifying agent, crospovidone, polyvinyl alcohol A kind of in sodium acrylate, polyethylene terephthalate phenol, preferred flocculant is chitosan; Concrete is the acetic acid solution that adds 1% chitosan (1g chitosan is dissolved in 100ml1% acetic acid solution) 10-50ml, preferably 20-35ml; the flocculation temperature is 20-90°C, preferably 60-80°C, and the clarification time is 30-300 minutes.
步骤(3)所用碱可为氢氧化钠、氢氧化钾、氢氧化钙及氨水等碱性物质,优选为5-15%的氢氧化钠。The alkali used in step (3) can be alkaline substances such as sodium hydroxide, potassium hydroxide, calcium hydroxide and ammonia water, preferably 5-15% sodium hydroxide.
步骤(4)所用稀酸可为硫酸、磷酸等0.1-15%的无机中强酸,优选为1-5%硫酸;所用碱同步骤(3)。The dilute acid used in step (4) can be sulfuric acid, phosphoric acid and other 0.1-15% inorganic medium strong acid, preferably 1-5% sulfuric acid; used alkali is the same as step (3).
文献报道从马钱子中提取士的宁经典方法如下:用石灰水浸泡马钱子,再以苯作溶剂提取并回收大部分苯后以盐酸萃取,萃取液析出士的宁粗结晶,重结晶获取高纯度的盐酸士的宁。缺点为溶剂价格高,环境污染大,安全性差(苯的毒性大),而且对设备要求严格,需严防溶剂泄露。与传统的士的宁制备技术相比,本法使用水为提取溶剂,环境污染小;生产设备要求低,不消耗有机溶剂,生产成本低。士的宁在水中溶解度极小,马钱子水提浓缩液调pH值至碱性时士的宁沉淀析出,但沉淀含大量杂质,后续制备工作难以开展,所以对马钱子水提浓缩液进行吸附澄清,澄清液调pH值至碱性则沉淀物中杂质含量大大降低,便于后续的精制。同时马钱子含最较多另一种生物碱——马钱子碱,马钱子碱在水中溶解度明显比士的宁高,因而在沉淀中含较少。与传统制备士的宁方法高相比,本法制备的产品纯度高。因此本发明作为一个整体全新方案,很适合从马钱子提取制备士的宁。According to literature reports, the classic method of extracting strychnine from Strychnine is as follows: Soak Strychnine with lime water, then use benzene as a solvent to extract and recover most of the benzene, then extract with hydrochloric acid, the extract solution precipitates strychnine coarse crystals, and recrystallizes Obtain High Purity Strychnine Hydrochloride. The disadvantages are that the price of the solvent is high, the environment is polluted, the safety is poor (benzene is highly toxic), and the equipment is strictly required to prevent solvent leakage. Compared with the traditional strychnine preparation technology, this method uses water as the extraction solvent, which has little environmental pollution; the production equipment has low requirements, no organic solvent is consumed, and the production cost is low. The solubility of strychnine in water is very small. Stychnine precipitates when the pH value of the water-extracted concentrate of Nuxychnium is adjusted to alkaline, but the precipitate contains a large amount of impurities, and subsequent preparation work is difficult to carry out. Therefore, the water-extracted concentrate of Nuxychnium Adsorption clarification is carried out, and the pH value of the clarified liquid is adjusted to alkaline, the impurity content in the precipitate is greatly reduced, which is convenient for subsequent refining. At the same time, strychnine contains the most another alkaloid - strychnine. Strychnine has a significantly higher solubility in water than strychnine, so it contains less in the precipitate. Compared with the traditional method for preparing strychnine, the product prepared by this method has high purity. Therefore the present invention, as a whole brand-new scheme, is very suitable for extracting and preparing strychnine from Semen Nuxychia.
具体实施方式 Detailed ways
下面通过实施例进一步说明本发明。应该理解的是,本发明的实施例是用于说明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明要求保护的范围。本发明各实施例所得的晶体均采用高效液相色谱法测定士的宁的含量,色谱条件如下:色谱柱C-18柱(4.6mm×250mm,5m),大连依特公司;流动相为乙腈-水(含0.01mol/L磷酸二氢钾和0.005mol/L庚烷磺酸钠,10%的磷酸调PH2.8)(21∶79);检测波长:260nm;柱温:40℃;流速:0.8ml/min。The present invention is further illustrated below by way of examples. It should be understood that the embodiments of the present invention are for illustration rather than limitation of the present invention. The simple improvements made to the present invention according to the essence of the present invention all belong to the protection scope of the present invention. The crystals obtained in each embodiment of the present invention all adopt high performance liquid chromatography to measure the content of strychnine, and the chromatographic conditions are as follows: chromatographic column C-18 column (4.6mm * 250mm, 5m), Dalian Yite Company; mobile phase is acetonitrile -Water (containing 0.01mol/L potassium dihydrogen phosphate and 0.005mol/L sodium heptanesulfonate, 10% phosphoric acid to adjust pH2.8) (21:79); detection wavelength: 260nm; column temperature: 40°C; flow rate : 0.8ml/min.
实施例一:Embodiment one:
取马钱子粗粉200克,第一次加水煎煮2000ml煎煮2小时,第二次加水煎煮1600ml煎煮1.5小时,第三次加水煎煮1200ml煎煮1.0小时。静置去滤渣,合并滤液,按照马钱子粗粉∶浓缩液=1g∶5ml的浓缩比例浓缩;加入含1%的壳聚糖的乙酸溶液200ml,80℃水浴吸附澄清。澄清液用10%的NaOH调pH值12,静置收集沉淀物A;沉淀物A用5%H2SO4溶解,滤过除去不溶物,再用10%的NaOH调pH值12,收集沉淀B。沉淀B用5%HCl溶解,过滤后结晶;粗结晶物溶解后重结晶,得95.3%盐酸士的宁0.86克。Get 200 grams of nux nuxya powder, add 2000ml of water and decoct for 2 hours for the first time, add 1600ml of water for decocting for 1.5 hours for the second time, add 1200ml of water for decocting and decoct for 1.0 hour for the third time. Leave to stand to remove the filter residue, combine the filtrates, and concentrate according to the concentration ratio of Nuxychon seed coarse powder: concentrated solution = 1g: 5ml; add 200ml of acetic acid solution containing 1% chitosan, and adsorb and clarify in a water bath at 80°C. Use 10% NaOH to adjust the pH value of the clarified solution to 12, and collect the precipitate A; dissolve the precipitate A with 5% H 2 SO 4 , filter to remove the insoluble matter, then adjust the pH value to 12 with 10% NaOH, and collect the precipitate b. Precipitate B was dissolved with 5% HCl, filtered and crystallized; the crude crystals were dissolved and recrystallized to obtain 0.86 g of 95.3% strychnine hydrochloride.
实施例二:Embodiment two:
取马钱子粗粉200克,第一次加水煎煮1600ml煎煮2小时,第二次加水煎煮1200ml煎煮1.5小时,第三次加水煎煮1200ml煎煮1.0小时。静置去滤渣,合并滤液,按照马钱子粗粉∶浓缩液=1g∶4ml的浓缩比例浓缩;加入含1%的壳聚糖的乙酸溶液250ml,60℃水浴吸附澄清。澄清液用10%的NaOH调pH值12,静置收集沉淀物A;沉淀物A用3%H2SO4溶解,滤过除去不溶物,再用10%的NaOH调pH值12,收集沉淀B。沉淀B用5%HCl溶解,过滤后结晶;粗结晶物溶解后重结晶,得94.9%盐酸士的宁0.81克。Get 200 grams of nux nuxya powder, add 1600ml of water and decoct for 2 hours for the first time, add 1200ml of water for decocting for 1.5 hours for the second time, add 1200ml of water for decocting for 1.0 hour for the third time. Leave to stand to remove the filter residue, combine the filtrates, concentrate according to the concentration ratio of Nuxychon seed coarse powder: concentrated solution = 1g: 4ml; add 250ml of acetic acid solution containing 1% chitosan, and adsorb and clarify in a water bath at 60°C. Use 10% NaOH to adjust the pH value of the clarified solution to 12, and collect the precipitate A; dissolve the precipitate A with 3% H 2 SO 4 , filter to remove the insoluble matter, then adjust the pH value to 12 with 10% NaOH, and collect the precipitate b. Precipitate B was dissolved with 5% HCl, filtered and crystallized; the crude crystals were dissolved and recrystallized to obtain 0.81 g of 94.9% strychnine hydrochloride.
实施例三:Embodiment three:
取马钱子粗粉200克,第一次加水煎煮2000ml煎煮2小时,第二次加水煎煮1600ml煎煮1.5小时。静置去滤渣,合并滤液,按照马钱子粗粉∶浓缩液=1g∶5ml的浓缩比例浓缩;加入含1%的壳聚糖的乙酸溶液220ml,80℃水浴吸附澄清。澄清液用10%的NaOH调pH值12,静置收集沉淀物A;沉淀物A用5%H2SO4溶解,滤过除去不溶物,再用10%的NaOH调pH值12,收集沉淀B。沉淀B用5%HCl溶解,过滤后结晶;粗结晶物溶解后重结晶,得94.7%盐酸士的宁0.73克。Get 200 grams of Nuxychnium seed meal, add 2000ml of water and decoct for 2 hours for the first time, add water and decoct for 1600ml for 1.5 hours for the second time. Leave to stand to remove filter residue, combine filtrate, concentrate according to the concentration ratio of Nuxychon seed coarse powder:concentrate=1g:5ml; Add 220ml of acetic acid solution containing 1% chitosan, 80 ℃ water bath adsorption clarification. Use 10% NaOH to adjust the pH value of the clarified solution to 12, and collect the precipitate A; dissolve the precipitate A with 5% H 2 SO 4 , filter to remove the insoluble matter, then adjust the pH value to 12 with 10% NaOH, and collect the precipitate b. Precipitate B was dissolved with 5% HCl, filtered and crystallized; the crude crystals were dissolved and recrystallized to obtain 0.73 g of 94.7% strychnine hydrochloride.
实施例四:Embodiment four:
取马钱子粗粉200克,第一次加水煎煮2000ml煎煮2小时,第二次加水煎煮1600ml煎煮1.5小时。静置去滤渣,合并滤液,按照马钱子粗粉∶浓缩液=1g∶4ml的浓缩比例浓缩;加入含1%的壳聚糖的乙酸溶液180ml,80℃水浴吸附澄清。澄清液用10%的NaOH调pH值12,静置收集沉淀物A;沉淀物A用5%H2SO4溶解,滤过除去不溶物,再用10%的NaOH调pH值12,收集沉淀B。沉淀B用5%HCl溶解,过滤后结晶;粗结晶物溶解后重结晶,得95.7%盐酸士的宁0.71克。Get 200 grams of Nuxychnium seed meal, add 2000ml of water and decoct for 2 hours for the first time, add water and decoct for 1600ml for 1.5 hours for the second time. Leave to stand to remove the filter residue, combine the filtrates, and concentrate according to the concentration ratio of Nuxychon seed coarse powder: concentrated solution = 1g: 4ml; add 180ml of acetic acid solution containing 1% chitosan, and adsorb and clarify in a water bath at 80°C. Use 10% NaOH to adjust the pH value of the clarified solution to 12, and collect the precipitate A; dissolve the precipitate A with 5% H 2 SO 4 , filter to remove the insoluble matter, then adjust the pH value to 12 with 10% NaOH, and collect the precipitate b. Precipitate B was dissolved with 5% HCl, filtered and crystallized; the crude crystals were dissolved and recrystallized to obtain 0.71 g of 95.7% strychnine hydrochloride.
对照例Comparative example
取马钱子粗粉200克,加300ml的石灰水浸泡后,第一次加氯仿煎煮2000ml煎煮2小时,第二次加氯仿煎煮1600ml煎煮1.5小时,第三次加氯仿煎煮1200ml煎煮1.0小时,合并滤液,回收氯仿至400ml,40ml6%HCl萃取,萃取液结晶;粗结晶物溶解后重结晶,得91.3%盐酸士的宁0.92克。Take 200 grams of nux nuxya powder, soak in 300ml of lime water, add 2000ml of chloroform for the first time and decoct for 2 hours, add 1600ml of chloroform for the second time and decoct for 1.5 hours, add chloroform for the third time and decoct 1200ml was decocted for 1.0 hour, combined filtrates, recovered chloroform to 400ml, extracted with 40ml 6% HCl, and the extract crystallized; the crude crystals were dissolved and recrystallized to obtain 0.92 g of 91.3% strychnine hydrochloride.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101743732A CN101838273B (en) | 2010-05-17 | 2010-05-17 | Method for Extracting Strychnine from Nuxychnium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101743732A CN101838273B (en) | 2010-05-17 | 2010-05-17 | Method for Extracting Strychnine from Nuxychnium |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101838273A CN101838273A (en) | 2010-09-22 |
CN101838273B true CN101838273B (en) | 2012-03-28 |
Family
ID=42741974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101743732A Expired - Fee Related CN101838273B (en) | 2010-05-17 | 2010-05-17 | Method for Extracting Strychnine from Nuxychnium |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101838273B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103159774B (en) * | 2011-12-09 | 2015-07-08 | 北京因科瑞斯医药科技有限公司 | Extraction, separation and purification method for strychnos total alkaloid |
CN105384747A (en) * | 2015-11-24 | 2016-03-09 | 正源堂(天津)生物科技有限公司 | Brucine extraction method |
CN108126018A (en) * | 2018-01-26 | 2018-06-08 | 湘潭大学 | A kind of method of the extraction purification rhubarb total anthraquinone from rheum officinale |
CN113694128B (en) * | 2021-07-27 | 2022-11-08 | 吉林化工学院 | Response surface method optimized extraction process of strychnine-containing alkaloids in carex meyeriana |
-
2010
- 2010-05-17 CN CN2010101743732A patent/CN101838273B/en not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
曾洁英等.不同溶剂条件提取马钱子时其成分与药效相关性的探讨.《中成药》.1994,第16卷(第8期),11-12. * |
李彦超等.马钱子总生物碱的测定及其提取条件的正交设计优选.《中药新药与临床药理》.2004,第15卷(第1期),43-46. * |
汤淮波等.不同溶剂提取马钱子中士的宁与马钱子碱的实验研究.《中医药导报》.2009,第15卷(第11期),52-53. * |
蒋以号等.马钱子及其不同炮制品水煎出物中士的宁和马钱子碱的含量测定.《中国中医药信息杂志》.2008,第15卷(第4期),47-49. * |
Also Published As
Publication number | Publication date |
---|---|
CN101838273A (en) | 2010-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022510832A (en) | Separation and purification method of cannabidiol by high-speed countercurrent chromatography | |
CN101838273B (en) | Method for Extracting Strychnine from Nuxychnium | |
CN101016328A (en) | Method for separating and purifying ursolic acid and oleanolic acid | |
CN101396432B (en) | Method for concentrating and separating flavonoids from toona sinensis leaves | |
CN107056615A (en) | A kind of method that high-purity chlorogenic acid is prepared from plant | |
CN101497637B (en) | Method for extracting high-purity scutellarin from breviscpini | |
JP6588072B2 (en) | Extraction and separation method of Eurycomanone from root of Tongkat ant | |
CN101805353A (en) | Preparation method of artemisinin | |
CN100390191C (en) | Method for extracting crude product baicalin from Scutellaria baicalensis | |
CN104418852B (en) | A kind of high-purity coptisine extracting method and application | |
CN102961422A (en) | Extraction method of high-purity ginseng extractive | |
CN105367424A (en) | Method for preparing high-purity chlorogenic acid from eupatorium adenophorum Spreng | |
CN108047292A (en) | A kind of method that high-purity rutoside is extracted from the sophora bud | |
CN111635440A (en) | Method for separating multiple active ingredients from immature bitter orange | |
WO2014114031A1 (en) | Mixed solvent for refining surfactants and surfactant purification method | |
CN104771713A (en) | Mulberry-ginger extract, and preparation process and application thereof | |
CN101224224A (en) | Method for extracting crude flavone and flavone glycoside from ginkgo leafs | |
CN104402801B (en) | Separate DNJ and the method preparing DNJ nano suspension | |
CN103012542A (en) | Method for extracting high-purity ursolic acid from paulownia leaves | |
CN104557953B (en) | One-step method is used to separate pectin, chlorophyll and the method for tigogenin in sisal hemp pressed liquor | |
CN114642738A (en) | A kind of veterinary water-soluble carrier with low temperature and high dissolution and preparation method thereof | |
CN103880798B (en) | A kind of method of purifying mycophenolic acid | |
CN113549118B (en) | Extraction method and application of high-purity triterpenoid saponin | |
CN111377824A (en) | Method for extracting levodopa from velvet beans | |
CN105732743A (en) | Method for preparing high-purity kaempferitrin by extracting from leaves of cinnamomum burmanii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120328 Termination date: 20160517 |